Jui-Shan Hsu

Jui-Shan Hsu

Auto-generated profile, based on publicly available information

Jui-Shan Hsu

Affiliation PATH, Seattle, Washington, United States of America

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Vaccine
Verified
Journal Article
Open access
JOJustin R. Ortiz
Justin R. Ortiz
JRJoanie Robertson
Joanie Robertson
JHJui-Shan Hsu
Jui-Shan Hsu
SYStephen Lee Yu
Stephen Lee Yu
ADAmanda J. Driscoll
Amanda J. Driscoll
KNKathleen M. Neuzil
Kathleen M. Neuzil
SARS-CoV-2 vaccines will be deployed to countries with limited immunization systems. We assessed the effect of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in a simulated WHO African Region country using region-specific data on immunization, population, healthcare workers (HCWs), cold storage capacity (quartile values for national and subnational levels), and characteristics of an approved SARS-CoV-2 vaccine. We calculated monthly increases in vaccine doses, doses per vaccinator, and cold storage volumes for four-month SARS-CoV-2 vaccination campaigns targeting risk groups compared to routine immunization baselines. Administering SARS-CoV-2 vaccines to risk groups would increase total monthly doses by 27.0% for ≥ 65 years, 91.7% for chronic diseases patients, and 1.1% for HCWs. Assuming median nurse density estimates adjusted for absenteeism and proportion providing immunization services, SARS-CoV-2 vaccination campaigns would increase total monthly doses per vaccinator by 29.3% for ≥ 65 years, 99.6% for chronic diseases patients, and 1.2% for HCWs. When we applied quartiles of actual African Region country vaccine storage capacity, routine immunization vaccine volumes exceeded national-level storage capacity for at least 75% of countries, but subnational levels had sufficient storage capacity for SARS-CoV-2 vaccines for at least 75% of countries. In the WHO African Region, SARS-CoV-2 vaccination campaigns would substantially increase doses per vaccinator and cold storage capacity requirements over routine immunization baselines. Pandemic vaccination campaigns would increase storage requirements of national-level stores already at their limits, but sufficient capacity exists at subnational levels. Immediate attention to strengthening immunization systems is essential to support pandemic responses.

1 August 2019 in Vaccine: X
Verified
Journal Article
Open access
MMMercy Mvundura
Mercy Mvundura
JHJui-Shan Hsu
Jui-Shan Hsu
CFCollrane Frivold
Collrane Frivold
DKDebra Kristensen
Debra Kristensen
SBShanda Boyle
Shanda Boyle
CJCourtney Jarrahian
Courtney Jarrahian
Inactivated poliovirus vaccine (IPV) shortages and evidence of improved immunogenicity of two intradermal (ID) fractional IPV (fIPV) doses compared with one full intramuscular dose led to recommendations for fIPV delivery. To provide evidence on the economics of fIPV, we estimated the cost per child vaccinated using full-dose IPV compared with fIPV in routine and campaign settings. We evaluated the impact on costs of alternative devices facilitating ID administration, vaccine vial sizes, and prices. We used an Excel-based model to estimate the commodity and delivery costs for providing IPV. Commodity costs included vaccine price per dose adjusted for wastage, prices for vaccine administration devices, and safety boxes. Delivery costs included storage costs at each level of the supply chain, transport costs for commodities between levels, and human resource costs for vaccine administration. Model inputs were obtained from various databases and published literature. All costs are reported in 2018 US dollars. In both campaign and routine settings, fIPV had a lower cost per child vaccinated than full dosing, despite the assumed higher vaccine wastage with fIPV in routine settings, and even when novel ID administration devices were used. In routine settings, costs per child fully vaccinated with fractional doses were 15% to 48% lower than those with full-dose delivery across different vial sizes. The cost per child vaccinated ranged from $1.84 to $2.65 for fractional doses, depending on the administration device, compared with $3.57 for full dose, when using 5-dose vials. The magnitude of cost reductions with fIPV relative to full-dose IPV was largest with smaller vial sizes and higher vaccine price. Adopting fIPV can reduce costs per child vaccinated compared with using full doses, especially as IPV prices increase in the short term and more so when two full doses could be recommended in the future.

19 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
MKMelissa Ko
Melissa Ko
CFCollrane Frivold
Collrane Frivold
MMMercy Mvundura
Mercy Mvundura
ASAdam Soble
Adam Soble
CGChristopher Gregory
Christopher Gregory
JAJean-Pierre Amorij
Jean-Pierre Amorij
Measles and rubella micro-array patches (MR-MAPs) are a promising innovation to address limitations of the current needle and syringe (N&S) presentation due to their single-dose presentation, ease of use, and improved thermostability. To direct and accelerate further research and interventions, an initial full value vaccine assessment (iFVVA) was initiated prior to MR-MAPs entering phase I trials to quantify their value and identify key data gaps and challenges. The iFVVA utilized a mixed-methods approach with rapid assessment of literature, stakeholder interviews and surveys, and quantitative data analyses to (i) assess global need for improved MR vaccines and how MR-MAPs could address MR problem statements; (ii) estimate costs and benefits of MR-MAPs; (iii) identify the best pathway from development to delivery; and (iv) identify outstanding areas of need where stakeholder intervention can be helpful. These analyses found that if MR-MAPs are broadly deployed, they can potentially reach an additional 80 million children compared to the N&S presentation between 2030–2040. MR-MAPs can avert up to 37 million measles cases, 400,000 measles deaths, and 26 million disability-adjusted life years (DALYs). MR-MAPs with the most optimal product characteristics of low price, controlled temperature chain (CTC) properties, and small cold chain volumes were shown to be cost saving for routine immunization (RI) in low- and middle-income countries (LMICs) compared to N&S. Uncertainties about price and future vaccine coverage impact the potential cost-effectiveness of introducing MR-MAPs in LMICs, indicating that it could be cost-effective in 16–81% of LMICs. Furthermore, this iFVVA highlighted the importance of upfront donor investment in manufacturing set-up and clinical studies and the critical influence of an appropriate price to ensure country and manufacturer financial sustainability. To ensure that MR-MAPs achieve the greatest public health benefit, MAP developers, vaccine manufacturers, donors, financiers, and policy- and decision-makers will need close collaboration and open communications.

4 May 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JOJustin R. Ortiz
Justin R. Ortiz
SYStephen L Yu
Stephen L Yu
ADAmanda J Driscoll
Amanda J Driscoll
SWSarah R Williams
Sarah R Williams
JRJoanie Robertson
Joanie Robertson
KNKathleen M Neuzil
Kathleen M Neuzil
Background: Influenza vaccination is uncommon in low-resource settings. We evaluated aspects of operational feasibility of influenza vaccination programs targeting risk groups in the World Health Organization (WHO) African (AFR) and South-East Asian (SEAR) Regions. Methods: We estimated routine immunization and influenza vaccination campaign doses, doses per vaccinator, and cold storage requirements for 1 simulated country in each region using evidence-based population distribution, vaccination schedule, and vaccine volumes. Influenza vaccination targeted persons <5 years, pregnant women, persons with chronic diseases, persons ≥65 years, and healthcare workers (HCW). For the AFR country, we compared vaccine volumes to actual storage capacities. Results: Targeting HCW had a small operational impact, and subsequent findings exclude this group. During 3-month influenza vaccination campaigns, monthly doses delivered in the AFR country increased from 15.0% for ≥65 years to 93.1% for <5 years and in the SEAR country from 19.6% for pregnant women to 145.0% for persons with chronic diseases. National-level cold storage capacity requirements increased in the AFR country from 4.1% for ≥65 years to 20.3% for <5 years and in the SEAR country from 3.9% for pregnant women to 28.8% for persons with chronic diseases. Subnational-level cold storage capacity requirements increased in the AFR country from 5.9% for ≥65 years to 36.8% for <5 years and the SEAR country from 17.6% for pregnant women to 56.0% for persons with chronic diseases. Conclusions: Influenza vaccination of most risk groups will require substantial increases in doses, doses per vaccinator, and cold storage capacity in countries where infrastructure and resources are limited.

14 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JOJustin R. Ortiz
Justin R. Ortiz
JRJoanie Robertson
Joanie Robertson
JHJui-Shan Hsu
Jui-Shan Hsu
SYStephen Lee Yu
Stephen Lee Yu
ADAmanda J. Driscoll
Amanda J. Driscoll
KNKathleen M. Neuzil
Kathleen M. Neuzil
Background: After SARS-CoV-2 vaccines become available, they will be deployed to many countries with limited immunization systems. Methods: We conducted a cold chain capacity assessment of a simulated country in the WHO African Region. We combined region-specific data regarding immunization, population, healthcare workforce, and cold storage capacity (upper and lower range and quartile values for national and subnational levels). We used seasonal influenza vaccines as proxies for SARS-CoV-2 vaccines. We evaluated the increase in vaccine doses to be administered, doses administered per vaccinator, and cold storage volumes for SARS-CoV-2 campaigns targeting risk groups compared to routine immunization baselines. Findings: Compared to routine immunization, a SARS-CoV-2 vaccination campaign would increase monthly doses administered when targeting risk groups: ≥65 years (29.9%), chronic diseases patients (101.5%), and healthcare workers (1.2%). SARS-CoV-2 vaccination campaigns would increase doses administered per vaccinator for risk groups: ≥65 years (32.5%), chronic diseases patients (110.4%), or healthcare workers (1.4%). Routine vaccine volumes already exceed national level storage capacity for at least 75% of African Region countries, but subnational levels would have sufficient storage capacity for SARS-CoV-2 vaccines in all but the lower 25% of African Region countries. Interpretation: SARS-CoV-2 vaccination campaigns would substantially increase doses per vaccinator and cold chain capacity requirements over routine immunization baselines. Pandemic vaccination campaigns would add volume to national level stores already at their limits, but substantial capacity exists at subnational levels for SARS-CoV-2 vaccines. Immediate attention to strengthening delivery systems is essential to support pandemic vaccine responses in the African Region. Funding: None

30 January 2026 in PLOS Water
Verified
Journal Article
Open access
PDF file
ADAdam Drolet
Adam Drolet
PCPatience Cofie
Patience Cofie
KAKofi Aburam
Kofi Aburam
EBEunice Yaa-Dapaah Boakye
Eunice Yaa-Dapaah Boakye
SHShan Hsu
Shan Hsu
AAAgnes Anane
Agnes Anane
Infection prevention and control is essential for high-quality health care. Chlorine is a widely used disinfectant in health care facilities; however, inconsistent availability and quality pose challenges for health staff. On-site chlorine production offers a potential solution. This study evaluates the reliability, change in chlorine availability and quality, and total cost of ownership of the Aqua Research STREAM Disinfectant Generator in primary health care facilities in Ghana. Our cross-sectional study evaluated 18 STREAM devices across 12 primary health care facilities in Ahafo, Central, and Volta Regions. A mean time between failures approach was used to benchmark device reliability. Historical commercial chlorine stock records were compared with STREAM chlorine production volumes. Chlorine quality assessments compared free residual chlorine levels in commercial and STEAM chlorine samples. A 5-year cost model estimated the total cost of STREAM ownership and per-liter cost savings potential. STREAM units remained functional for 94.8% of the study; 67% (n = 12) functioned without failure. Six devices averaged 60.8 days before their first failure (range 16–96 days). No device recorded more than one component failure. STREAM devices eliminated chlorine stock outs, previously occurring 37 days per year on average. In all, 83% of health facilities were found to have degraded commercial chlorine, whereas 100% of STREAM samples met the device’s target concentration (0.5% ± 0.1% mg/L). The 5-year total cost of ownership ranged from $3,700 to $7,900. District hospitals saw a 17% reduction in annual chlorine supply costs with STREAM units, while health centers experienced an increase of 48%. The STREAM shows promise for improving infection prevention and control practices in Ghana’s health system. Study results informed the Ghana Health Service’s decision to purchase 400 STREAM devices (June 2024). Future research should explore operational models that expand chlorine availability and lower chlorine costs in health facilities.